These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

293 related articles for article (PubMed ID: 17627937)

  • 1. Liver-specific activities of FGF19 require Klotho beta.
    Lin BC; Wang M; Blackmore C; Desnoyers LR
    J Biol Chem; 2007 Sep; 282(37):27277-27284. PubMed ID: 17627937
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Differential specificity of endocrine FGF19 and FGF21 to FGFR1 and FGFR4 in complex with KLB.
    Yang C; Jin C; Li X; Wang F; McKeehan WL; Luo Y
    PLoS One; 2012; 7(3):e33870. PubMed ID: 22442730
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Glycosylation of fibroblast growth factor receptor 4 is a key regulator of fibroblast growth factor 19-mediated down-regulation of cytochrome P450 7A1.
    Triantis V; Saeland E; Bijl N; Oude-Elferink RP; Jansen PL
    Hepatology; 2010 Aug; 52(2):656-66. PubMed ID: 20683963
    [TBL] [Abstract][Full Text] [Related]  

  • 4. FGF19 regulates cell proliferation, glucose and bile acid metabolism via FGFR4-dependent and independent pathways.
    Wu AL; Coulter S; Liddle C; Wong A; Eastham-Anderson J; French DM; Peterson AS; Sonoda J
    PLoS One; 2011 Mar; 6(3):e17868. PubMed ID: 21437243
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular elements in FGF19 and FGF21 defining KLB/FGFR activity and specificity.
    Agrawal A; Parlee S; Perez-Tilve D; Li P; Pan J; Mroz PA; Kruse Hansen AM; Andersen B; Finan B; Kharitonenkov A; DiMarchi RD
    Mol Metab; 2018 Jul; 13():45-55. PubMed ID: 29789271
    [TBL] [Abstract][Full Text] [Related]  

  • 6. IL-1β inhibits β-Klotho expression and FGF19 signaling in hepatocytes.
    Zhao Y; Meng C; Wang Y; Huang H; Liu W; Zhang JF; Zhao H; Feng B; Leung PS; Xia Y
    Am J Physiol Endocrinol Metab; 2016 Feb; 310(4):E289-300. PubMed ID: 26670488
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tissue-specific expression of betaKlotho and fibroblast growth factor (FGF) receptor isoforms determines metabolic activity of FGF19 and FGF21.
    Kurosu H; Choi M; Ogawa Y; Dickson AS; Goetz R; Eliseenkova AV; Mohammadi M; Rosenblatt KP; Kliewer SA; Kuro-O M
    J Biol Chem; 2007 Sep; 282(37):26687-26695. PubMed ID: 17623664
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Selective activation of FGFR4 by an FGF19 variant does not improve glucose metabolism in ob/ob mice.
    Wu X; Ge H; Lemon B; Weiszmann J; Gupte J; Hawkins N; Li X; Tang J; Lindberg R; Li Y
    Proc Natl Acad Sci U S A; 2009 Aug; 106(34):14379-84. PubMed ID: 19706524
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Monomeric/dimeric forms of Fgf15/FGF19 show differential activity in hepatocyte proliferation and metabolic function.
    Williams CM; Harper Calderon J; E H; Jimenez Y; Barringer K; Carbonaro M; Molina-Portela MDP; Thurston G; Li Z; Daly C
    FASEB J; 2021 Feb; 35(2):e21286. PubMed ID: 33484478
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Klotho-beta and fibroblast growth factor 19 expression correlates with early recurrence of resectable hepatocellular carcinoma.
    Lin ZZ; Hsu C; Jeng YM; Hu FC; Pan HW; Wu YM; Hsu HC; Hu MC; Cheng AL
    Liver Int; 2019 Sep; 39(9):1682-1691. PubMed ID: 30698907
    [TBL] [Abstract][Full Text] [Related]  

  • 11. FGFR redundancy limits the efficacy of FGFR4-selective inhibitors in hepatocellular carcinoma.
    Tao Z; Cui Y; Xu X; Han T
    Proc Natl Acad Sci U S A; 2022 Oct; 119(40):e2208844119. PubMed ID: 36179047
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Co-receptor requirements for fibroblast growth factor-19 signaling.
    Wu X; Ge H; Gupte J; Weiszmann J; Shimamoto G; Stevens J; Hawkins N; Lemon B; Shen W; Xu J; Veniant MM; Li YS; Lindberg R; Chen JL; Tian H; Li Y
    J Biol Chem; 2007 Oct; 282(40):29069-72. PubMed ID: 17711860
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting the FGF19-FGFR4 pathway for cholestatic, metabolic, and cancerous diseases.
    Li X; Lu W; Kharitonenkov A; Luo Y
    J Intern Med; 2024 Mar; 295(3):292-312. PubMed ID: 38212977
    [TBL] [Abstract][Full Text] [Related]  

  • 14. First Selective Small Molecule Inhibitor of FGFR4 for the Treatment of Hepatocellular Carcinomas with an Activated FGFR4 Signaling Pathway.
    Hagel M; Miduturu C; Sheets M; Rubin N; Weng W; Stransky N; Bifulco N; Kim JL; Hodous B; Brooijmans N; Shutes A; Winter C; Lengauer C; Kohl NE; Guzi T
    Cancer Discov; 2015 Apr; 5(4):424-37. PubMed ID: 25776529
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The central fibroblast growth factor receptor/beta klotho system: Comprehensive mapping in Mus musculus and comparisons to nonhuman primate and human samples using an automated in situ hybridization platform.
    Hultman K; Scarlett JM; Baquero AF; Cornea A; Zhang Y; Salinas CBG; Brown J; Morton GJ; Whalen EJ; Grove KL; Koegler FH; Schwartz MW; Mercer AJ
    J Comp Neurol; 2019 Aug; 527(12):2069-2085. PubMed ID: 30809795
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hepatocyte FRS2α is essential for the endocrine fibroblast growth factor to limit the amplitude of bile acid production induced by prandial activity.
    Wang C; Yang C; Chang JY; You P; Li Y; Jin C; Luo Y; Li X; McKeehan WL; Wang F
    Curr Mol Med; 2014; 14(6):703-711. PubMed ID: 25056539
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fibroblast growth factor receptor 4 (FGFR4) and fibroblast growth factor 19 (FGF19) autocrine enhance breast cancer cells survival.
    Tiong KH; Tan BS; Choo HL; Chung FF; Hii LW; Tan SH; Khor NT; Wong SF; See SJ; Tan YF; Rosli R; Cheong SK; Leong CO
    Oncotarget; 2016 Sep; 7(36):57633-57650. PubMed ID: 27192118
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interrupting the FGF19-FGFR4 Axis to Therapeutically Disrupt Cancer Progression.
    Lang L; Shull AY; Teng Y
    Curr Cancer Drug Targets; 2019; 19(1):17-25. PubMed ID: 29557750
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of fibroblast growth factor 19 reduces tumor growth by modulating beta-catenin signaling.
    Pai R; Dunlap D; Qing J; Mohtashemi I; Hotzel K; French DM
    Cancer Res; 2008 Jul; 68(13):5086-95. PubMed ID: 18593907
    [TBL] [Abstract][Full Text] [Related]  

  • 20. FXR Primes the Liver for Intestinal FGF15 Signaling by Transient Induction of β-Klotho.
    Fu T; Kim YC; Byun S; Kim DH; Seok S; Suino-Powell K; Xu HE; Kemper B; Kemper JK
    Mol Endocrinol; 2016 Jan; 30(1):92-103. PubMed ID: 26505219
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.